ESR1 and breast carcinoma: To investigate the rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant TAM administration and to compare the results with the meta‐analysis data of HR‐discordance studies.